Novartis has invested over $300 million in the last 5 years in India. In India, portfolio of Novartis has both innovative and established medicines in the segments of cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant Swiss pharma giant Novartis will evaluate India to scale up its manufacturing capabilities and technology advancements, in future, if needed, said Vas Narasimhan, global Chief Executive Officer (CEO) of Novartis.
Novartis has invested over $300 million in the last 5 years in India. In India, portfolio of Novartis has both innovative and established medicines in the segments of cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant.
“When we do need more manufacturing capacity or in any technology area, we would certainly evaluate Hyderabad, India on par with any other place in the world to do this work,” said Narasimhan on the sidelines of BioAsia 2023, the 20th edition of Telangana’s annual flagship life sciences and healthcare event.
India is amongst a handful of countries in the world that have a broad Novartis footprint covering early research, drug development, technical operations, business services and commercial operations.
